

# Imaging in CAD

Jeroen J Bax

Dept of Cardiology

Leiden Univ Medical Center

The Netherlands

Varna, oct 2014

Research grants: Medtronic, Biotronik, Boston Scientific,  
St Jude, BMS imaging, GE Healthcare, Edwards  
Lifescience

# 4 major imaging techniques:

- **Echocardiography**
- **Magnetic resonance imaging**
- **Multi-slice CT**
- **Nuclear imaging (PET and SPECT)**
- **Can provide all anatomical and functional information, but use should be clinically driven**

Diagnosis is important

But the imaging results need  
to have impact on choice of  
therapy

# From atherosclerosis to heart failure: Where may imaging help?

✂️👉 **Asymptomatic patients**

**at elevated risk for atherosclerosis/CVD:  
screening / early detection**

- **Symptomatic patients: detection of coronary artery disease**
- **Ischemic heart failure: extensive evaluation**

# **Patient example**

**Woman 48 years old**

**Outpatient clinics:**

**No symptoms**

**Risk factors for CAD:**

**\*Family history of CAD**

Asymptomatic individual,  
low risk

The question is:

Risk stratification


Blood:  
biomarkers

Early  
detection  
of CVD

Large arteries:  
Global: atherosclerosis

Coronary arteries:  
Focal: lesion characteristics

# Cardiovascular event-free survival, according to CRP and LDL





Blood:  
biomarkers


Early  
detection  
of CVD

Large arteries:  
Global: atherosclerosis

Coronary arteries:  
Focal: lesion characteristics

# Carotid Intima Media Thickness (CIMT)

Tissue between luminal edge of the artery  
and the boundary between  
media and adventitia



**I** = Intima

**M** = Media

**A** = Adventitia


# Assessment of CIMT

Semi-automatic B-mode ultrasound measurements

Left and right common carotid artery, directly proximal to the bifurcation

Mean CIMT measurements at four angles


Calculation of the average of 8 mean CIMT per patient



# CIMT in the general population

- **Increases with age  
and cardiovascular risk factors**
- **Correlates with presence of  
cardiovascular disease**
- **Independent predictor of  
cardiovascular events**

# Cumulative event free rate (stroke or MI) according to IMT quintiles



Blood:  
biomarkers

Early  
detection  
of CVD

Large arteries:  
Global: atherosclerosis


Coronary arteries:  
Focal: lesion characteristics

# Calcium Scoring (EBCT/MSCT)

No  
calcification


Moderate  
calcification

Extensive  
calcification



**Coronary calcifications provide a marker for  
atherosclerotic disease burden**

# Calcium scoring (EBCT/MSCT)



## CAC Score Calcified Plaque Burden

0 No identifiable atherosclerotic plaque

1-10 Minimal plaque burden

11-100 Mild plaque burden


101-400 Moderate plaque burden

401-1,000 Extensive plaque burden

>1,000 Very extensive plaque burden



# Calcium score vs risk stratification



# Calcium Scoring (EBCT/MSCT)

- Presence of coronary calcifications associated with increased risk of coronary events
- Marker for CAD in general, rather than marker for specific site
- Unable to identify localized vulnerable plaque
- Population risk marker rather than individual specific

# Screening for CVD

- **What (blood, large vessels, coronary arteries) do we screen?**
- **Will it improve outcome?**
- **When do we screen?**
- **Do we need to screen periodically?**
- **What are the therapeutic consequences?**

# From atherosclerosis to heart failure: Where may imaging help?

- **Asymptomatic patients**  
at elevated risk for atherosclerosis/CVD:  
screening / early detection
- ✂️ **Symptomatic patients: detection of**  
**coronary artery disease**
- **Ischemic Heart failure: extensive evaluation**

# Patient example

Man 47 years old


Outpatient clinics:

Dyspnea or atypical chest pain at exercise


Risk factors for CAD:

\*Dyslipidemia

# Non-invasive assessment of CAD: Which Patients?



# Non-invasive assessment of CAD: Which Patients?



# Symptomatic patient, low-intermed risk


The question is:

Atherosclerosis? (medical therapy needed and follow-up or discharge?)


☞ We order a non-invasive anatomical test to detect /exclude atherosclerosis




# MRI – angiography (1.5T)



Leiden, NL




Aarhus, DK



Munich, GER



Boston, USA




Berlin, GER



Leeds, UK




Kurashiki, JP






St. Louis, USA


# MRI - angiography






Stronger magnets:  
3T coronary imaging




# CT angiography - raw data




# curved MPR



**RCA**




**LAD**



**LCX**

# Meta-analysis 64-slice CT


Patient-based detection (n=1286)




- $\geq 50\%$  stenosis
- versus CAG
- Not assessable:  
4% (0-14%)

# 320-CT

## Coverage of the heart in 1 rotation



16 cm



# Patient example

Man 47 years old


Outpatient clinics:

Dyspnea or atypical chest pain at exercise


Risk factors for CAD:

\*Dyslipidemia

# Non-invasive angiography - MSCT



LAD: normal,  
intramural course mid



LCx: normal



# 320-CT – rule out CAD

57 yr old woman, 2x TIA

Analysis cardiac source of embolism




# 320-CT – rule out CAD


Smoking 39 pack years

Severe dyslipidemia (chol 7.8 mmol/L)

MSCT angiography to exclude (?) CAD



LAD



LCx




RCA

No significant stenosis

# Prognosis MSCT

13,966 pts, mean F-up 22.5 months



# Patient example

Man 58 years old

Outpatient clinics:

chest pain at rest, sometimes stress


Risk factors for CAD:

- \*Hypercholesterolemia

- \*Hypertension

- \*Smoking

# Non-invasive assessment of CAD: Which Patients?




Symptomatic patient,  
intermed – high pre-test  
likelihood

The patient has high likelihood to have  
atherosclerosis

The question is: does he have ischemia?  
(is intervention needed?)

☞ We order a non-invasive ischemia test

# The ischemic cascade




# Ischemia as an expression of a flow-limiting stenosis


- **Assessment of**
  - perfusion abnormalities (stress-inducible)
- **Assessment of**
  - systolic wall motion abnormalities (stress-inducible)



# Nuclear perfusion imaging, SPECT



POLAR MAP TO QUANTIFY  
EXTENT AND SEVERITY OF ISCHEMIA



# Nuclear perfusion imaging with ECG gating

- **Permits assessment of LVEF, LV volumes and regional function**
- **At rest and stress**



# Stress echo to assess flow-limiting stenosis: wall motion

**rest**

**10 mcg**

**40**

**rest**





Addition on intravenous contrast  
to improve border opacification



# Stress MRI to assess flow-limiting stenosis: wall motion



# MRI – perfusion imaging



# Comparison of imaging techniques for diagnosis of CAD

- **In low-intermediate likelihood:**
  - atherosclerosis imaging (non-invasive angiography)
  - MSCT preferred over MRI
- **In intermediate-high likelihood:**
  - ischemia imaging
  - all modern techniques can assess perfusion and systolic function

# From atherosclerosis to heart failure: Where may imaging help?

- **Asymptomatic patients  
at elevated risk for atherosclerosis/CVD:  
screening / early detection**
- ✂️👉 **Symptomatic patients: detection of coronary  
artery disease**
- ✂️👉 **Ischemic heart failure: extensive  
evaluation**



# Patient example

Male, 62 yrs

- 1987: Infero-postero-lateral infarct
- 1988: Repeat inferior infarct
- 1994: Antero-septal infarct
- 1996: CABG: LIMA-graft LAD,  
venous graft MO-LCX and RDP/RCA
- 2000: Non-sustained ventricular tachycardia

## Co-morbidities

- Diabetes II
- COPD
- chronic renal failure (creatinine 300 micromol/l)

# Patient example

Male, 62 yrs

- Reduced exercise capacity
- NYHA III
- Dizziness / Hypotension
  
- Weight 53 kg, length 1.64 m
- RR 90/65 mmHg
- Holosystolic murmur 3/6 apex

# Severe heart failure patient

To determine therapy, the information below is needed


**LV function and LV size?**

**CAD: ischemia/viability?**

**Severe MR?**

**ICD needed?**

# LV function and size?



# LV function and size?




# **LV function and size? Towards 3D imaging?**





# LV function and size?

- We need:
- Highest resolution images in every patient
- Assessment of LVEF but also
  - LV dimensions : LVESD, LVEDD
  - LV volumes: LVESV, LVEDV
- Exact quantification – prognosis but also for justification of ICD therapy

# Advanced LV function assessment







Longitudinal strain






# From regional to global LV strain






# Global strain maps: HF, infarction, and normal



GLPSS Avg:  $-7.3 \pm 3\%$

GLPSS Avg:  $-13.8 \pm 3.3\%$

GLPSS Avg:  $-19.1 \pm 3.1\%$




# Is there viability?

to predict prognosis post-surgery


N= 20 studies, 2362 pts

All retrospective analyses




# Is there viability?



FDG



Perf




# Infarct imaging with delayed enhancement MRI



# Viability assessment - Future?



# Severe MR affects prognosis



# Severe MR?




TTE




TEE



# Is quantification of MR severity needed?




# MRI: 3D Flow Quantification in All Valves



# MRI: 3D Flow Quantification mitral valve



MV flow



$$V_{\text{forward}} = 116 \text{ ml}$$

$$V_{\text{back}} = 32 \text{ ml}$$

$$V_{\text{eff}} = 84 \text{ ml}$$

$$\text{Regurg. Fraction} = 27\%$$


# Severe MR – other techniques?



3D TTE

# Importance of MV anatomy

## Is surgical repair feasible?



3D TEE

# ICD needed?

- Patients with:  
previous infarction  
LVEF <30%
- Benefit from ICD:
- MADIT II: improved survival

# ICD needed?

## ICD shocks in primary prevention


percentage N=720 pts, MADIT II  
Follow-up 21 months  
Shocks:

100

70

40

10




65

35

-

+



# What is the pathophysiological substrate for SCD in CAD?



*Courtesy W Stevenson*




# MRI to assess arrhythmogenic substrate:



- Late-gadolinium enhancement: scar area and peri-infarct zone

# Value of border zone to predict VTs



HR (95%CI): 1.47 (1.04 to 2.08)  
P = 0.003

# **Severe heart failure patient**

**Complex information is needed to determine therapy**

**Can be provided by multi-modality imaging**

# Conclusions

- **Virtually all anatomical and functional information can be obtained by (a combination) of the available imaging techniques**
- **The choice of techniques should be guided by the information needed**
- **Implementation of pre-defined care tracks may promote systematic use of the different techniques**